These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11106654)

  • 1. Interaction with p53 enhances binding of cisplatin-modified DNA by high mobility group 1 protein.
    Imamura T; Izumi H; Nagatani G; Ise T; Nomoto M; Iwamoto Y; Kohno K
    J Biol Chem; 2001 Mar; 276(10):7534-40. PubMed ID: 11106654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential binding of HMG1, HMG2, and a single HMG box to cisplatin-damaged DNA.
    Farid RS; Bianchi ME; Falciola L; Engelsberg BN; Billings PC
    Toxicol Appl Pharmacol; 1996 Dec; 141(2):532-9. PubMed ID: 8975778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo acetylation of HMG1 protein enhances its binding affinity to distorted DNA structures.
    Ugrinova I; Pasheva EA; Armengaud J; Pashev IG
    Biochemistry; 2001 Dec; 40(48):14655-60. PubMed ID: 11724579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin.
    Pil PM; Lippard SJ
    Science; 1992 Apr; 256(5054):234-7. PubMed ID: 1566071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural and kinetic studies of a cisplatin-modified DNA icosamer binding to HMG1 domain B.
    Jamieson ER; Jacobson MP; Barnes CM; Chow CS; Lippard SJ
    J Biol Chem; 1999 Apr; 274(18):12346-54. PubMed ID: 10212205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of high mobility group protein binding to cisplatin-damaged DNA.
    Billings PC; Davis RJ; Engelsberg BN; Skov KA; Hughes EN
    Biochem Biophys Res Commun; 1992 Nov; 188(3):1286-94. PubMed ID: 1445361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional activation of the human HMG1 gene in cisplatin-resistant human cancer cells.
    Nagatani G; Nomoto M; Takano H; Ise T; Kato K; Imamura T; Izumi H; Makishima K; Kohno K
    Cancer Res; 2001 Feb; 61(4):1592-7. PubMed ID: 11245470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human mitochondrial transcription factor A binds preferentially to oxidatively damaged DNA.
    Yoshida Y; Izumi H; Ise T; Uramoto H; Torigoe T; Ishiguchi H; Murakami T; Tanabe M; Nakayama Y; Itoh H; Kasai H; Kohno K
    Biochem Biophys Res Commun; 2002 Jul; 295(4):945-51. PubMed ID: 12127986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stopped-flow fluorescence studies of HMG-domain protein binding to cisplatin-modified DNA.
    Jamieson ER; Lippard SJ
    Biochemistry; 2000 Jul; 39(29):8426-38. PubMed ID: 10913248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single HMG domain in high-mobility group 1 protein binds to DNAs as small as 20 base pairs containing the major cisplatin adduct.
    Chow CS; Barnes CM; Lippard SJ
    Biochemistry; 1995 Mar; 34(9):2956-64. PubMed ID: 7893709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen.
    Ise T; Nagatani G; Imamura T; Kato K; Takano H; Nomoto M; Izumi H; Ohmori H; Okamoto T; Ohga T; Uchiumi T; Kuwano M; Kohno K
    Cancer Res; 1999 Jan; 59(2):342-6. PubMed ID: 9927044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formation of large nucleoprotein complexes upon binding of the high-mobility-group (HMG) box B-domain of HMG1 protein to supercoiled DNA.
    Stros M; Reich J
    Eur J Biochem; 1998 Jan; 251(1-2):427-34. PubMed ID: 9492314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intercalating residues determine the mode of HMG1 domains A and B binding to cisplatin-modified DNA.
    He Q; Ohndorf UM; Lippard SJ
    Biochemistry; 2000 Nov; 39(47):14426-35. PubMed ID: 11087395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HMG1 interacts with HOX proteins and enhances their DNA binding and transcriptional activation.
    Zappavigna V; Falciola L; Helmer-Citterich M; Mavilio F; Bianchi ME
    EMBO J; 1996 Sep; 15(18):4981-91. PubMed ID: 8890171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photoreactivity of platinum(II) in cisplatin-modified DNA affords specific cross-links to HMG domain proteins.
    Kane SA; Lippard SJ
    Biochemistry; 1996 Feb; 35(7):2180-8. PubMed ID: 8652559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in the DNA-binding properties of the HMG-box domains of HMG1 and the sex-determining factor SRY.
    Teo SH; Grasser KD; Thomas JO
    Eur J Biochem; 1995 Jun; 230(3):943-50. PubMed ID: 7601157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physical interaction of tumour suppressor p53/p73 with CCAAT-binding transcription factor 2 (CTF2) and differential regulation of human high-mobility group 1 (HMG1) gene expression.
    Uramoto H; Izumi H; Nagatani G; Ohmori H; Nagasue N; Ise T; Yoshida T; Yasumoto K; Kohno K
    Biochem J; 2003 Apr; 371(Pt 2):301-10. PubMed ID: 12534345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracellular distribution of HMG1, HMG2 and UBF change following treatment with cisplatin.
    Chao JC; Wan XS; Engelsberg BN; Rothblum LI; Billings PC
    Biochim Biophys Acta; 1996 Jun; 1307(2):213-9. PubMed ID: 8679707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcium binding to HMG1 protein induces DNA looping by the HMG-box domains.
    Stros M; Reich J; Kolíbalová A
    FEBS Lett; 1994 May; 344(2-3):201-6. PubMed ID: 8187884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P53 physically interacts with mitochondrial transcription factor A and differentially regulates binding to damaged DNA.
    Yoshida Y; Izumi H; Torigoe T; Ishiguchi H; Itoh H; Kang D; Kohno K
    Cancer Res; 2003 Jul; 63(13):3729-34. PubMed ID: 12839966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.